Targeted protein degradation gains momentum as Kymera Therapeutics expands partnerships and clinical candidates. The company’s collaboration with Sanofi pivots to advancing a new IRAK4 degrader while also securing a lucrative agreement with Gilead to develop CDK2 molecular glues for breast and solid tumors. This strategic portfolio adjustment underscores growing confidence in protein degraders to offer selective and efficacious cancer therapies, challenging traditional small molecule approaches.